Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peg-liposomal dexamethasone sodium phosphate
- Development stage
- Phase 1
- Lead developer
- Enceladus Pharmaceuticals
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
PEG-liposomal dexamethasone sodium phosphate (ENC-0313, Oncocort) is a pegylated liposomal formulation of the glucocorticoid dexamethasone sodium phosphate. Developed by Enceladus Pharmaceuticals, it consists of ~100 nm vesicles composed of dipalmitoyl phosphatidyl choline (DPPC), PEGylated distearoyl phosphatidyl ethanolamine (PEG-DSPE), and cholesterol. This formulation is designed to provide prolonged systemic circulation and enhanced accumulation at sites of inflammation or malignancy (via the enhanced permeability and retention effect) compared to conventional dexamethasone. It acts as a glucocorticoid receptor agonist. The drug has been evaluated in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and multiple myeloma.
- Brand names
- Oncocort
- Other names
- PEGylated liposomal dexamethasone sodium phosphateLiposomal dexamethasone sodium phosphate
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on peg-liposomal dexamethasone sodium phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peg-liposomal dexamethasone sodium phosphate.